Monthly Archives: October 2016

http://www.lslog.com/with-7b-buyout-wrapped-mylan-plans-to-shutter-medas-u-s-headquarters-cut-94-jobs/With $7B buyout wrapped, Mylan plans to shutter Meda's U.S. headquarters, cut 94 jobs

With $7B buyout wrapped, Mylan plans to shutter Meda's U.S. headquarters, cut 94 jobs

With B buyout wrapped, Mylan plans to shutter Meda’s U.S. headquarters, cut 94 jobs With $7B buyout wrapped, Mylan plans to shutter Meda’s U.S. headquarters, cut 94 jobs esagonowsky Mon, […]

http://www.lslog.com/takeda-ceo-says-new-myeloma-drug-ninlaro-will-be-significantly-bigger-than-velcade/Takeda CEO says new myeloma drug Ninlaro will be 'significantly bigger than Velcade'

Takeda CEO says new myeloma drug Ninlaro will be 'significantly bigger than Velcade'

Takeda CEO says new myeloma drug Ninlaro will be ‘significantly bigger than Velcade’ Takeda CEO says new myeloma drug Ninlaro will be ‘significantly bigger than Velcade’ phil Mon, 10/31/2016 – […]

http://www.lslog.com/novo-nordisk-kills-oral-insulin-rejigs-rd-to-address-u-s-payers/Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers

Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers

Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers slawrence Mon, 10/31/2016 – 10:19 Source: FierceMedicalDevices […]

http://www.lslog.com/sanofiregeneron-hit-with-fda-delay-for-sarilumab/Sanofi/Regeneron hit with FDA delay for sarilumab

Sanofi/Regeneron hit with FDA delay for sarilumab

Sanofi/Regeneron hit with FDA delay for sarilumab Sanofi/Regeneron hit with FDA delay for sarilumab badams Mon, 10/31/2016 – 04:45 Source: FierceMedicalDevices News Sanofi/Regeneron hit with FDA delay for sarilumab

http://www.lslog.com/poor-humira-performance-triggers-q3-sales-miss-for-abbvie-but-sga-beat-keeps-eps-in-line/'Poor' Humira performance triggers Q3 sales miss for AbbVie, but SG&A beat keeps EPS in line

'Poor' Humira performance triggers Q3 sales miss for AbbVie, but SG&A beat keeps EPS in line

‘Poor’ Humira performance triggers Q3 sales miss for AbbVie, but SG&A beat keeps EPS in line ‘Poor’ Humira performance triggers Q3 sales miss for AbbVie, but SG&A beat keeps EPS […]

http://www.lslog.com/biogens-tecfidera-amgens-enbrel-tell-a-tale-of-pricing-power-and-weakness/Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness

Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness

Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness tracy Fri, 10/28/2016 – 11:00 […]

http://www.lslog.com/astellas-snaps-up-cancer-antibody-play-ganymed-for-up-to-1-4b/Astellas snaps up cancer antibody play Ganymed for up to $1.4B

Astellas snaps up cancer antibody play Ganymed for up to $1.4B

Astellas snaps up cancer antibody play Ganymed for up to .4B Astellas snaps up cancer antibody play Ganymed for up to $1.4B slawrence Fri, 10/28/2016 – 10:10 Source: FierceMedicalDevices […]

http://www.lslog.com/tesaros-parp-accepted-for-review-in-eu-as-az-makes-case-for-lynparza/Tesaro’s PARP accepted for review in EU as AZ makes case for Lynparza

Tesaro’s PARP accepted for review in EU as AZ makes case for Lynparza

Tesaro’s PARP accepted for review in EU as AZ makes case for Lynparza Tesaro’s PARP accepted for review in EU as AZ makes case for Lynparza badams Fri, 10/28/2016 – […]

http://www.lslog.com/astrazeneca-down-on-partial-hold-for-phiii-pd-l1-candidate/AstraZeneca down on partial hold for PhIII PD-L1 candidate

AstraZeneca down on partial hold for PhIII PD-L1 candidate

AstraZeneca down on partial hold for PhIII PD-L1 candidate AstraZeneca down on partial hold for PhIII PD-L1 candidate slawrence Thu, 10/27/2016 – 15:10 Source: FierceMedicalDevices News AstraZeneca down on […]

http://www.lslog.com/amazons-bezos-mayo-clinic-back-unity-in-116m-series-b-to-slow-diseases-of-aging/Amazon's Bezos, Mayo Clinic back Unity in $116M Series B to slow diseases of aging

Amazon's Bezos, Mayo Clinic back Unity in $116M Series B to slow diseases of aging

Amazon’s Bezos, Mayo Clinic back Unity in 6M Series B to slow diseases of aging Amazon’s Bezos, Mayo Clinic back Unity in $116M Series B to slow diseases of aging […]